Sarepta Therapeutics
SRPT
120 hedge funds and large institutions have $359M invested in Sarepta Therapeutics in 2014 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 29 reducing their positions, and 26 closing their positions.
154% more call options, than puts
Call options by funds: $63.5M | Put options by funds: $25M
55% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
2% less funds holding
Funds holding: 123 → 120 (-3)
34% less capital invested
Capital invested by funds: $548M → $359M (-$189M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.44M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$5.94M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$4.07M |
| 5 |
PA
Perceptive Advisors
New York
|
+$3.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$21.6M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$14.7M |
| 3 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$11M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$8.45M |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$8.26M |
SRPT Hedge Fund Activity: Q4 2014 in Review
120 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2014, worth a combined $359M — down 34% from $548M a quarter earlier.
Fund positioning in SRPT was balanced in Q4 2014: 26 funds opened new positions, 26 closed out, 45 added to existing stakes and 29 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $22.4M. The largest seller was Jennison Associates, exiting entirely with an estimated $21.6M sold.
- 120 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2014, down from 123 in Q3 2014.
- Funds reported $359M of Sarepta Therapeutics stock for Q4 2014, down 34% quarter-over-quarter.
- 26 funds opened new Sarepta Therapeutics positions in Q4 2014 and 26 closed out, a net change of 0 holders.
- The largest Sarepta Therapeutics buyer in Q4 2014 was Point72 Asset Management, an estimated $22.4M added.
- The largest Sarepta Therapeutics seller in Q4 2014 was Jennison Associates, an estimated $21.6M sold.
Based on aggregated 13F filings for Q4 2014.